Compositions and methods for reducing cytokine expression
AssigneeEvelo Biosciences, Inc.
InventorsDavid Epstein, Duncan McHale
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-Iβ, and/C or TNFα expression and/or for the treatment of viral infections.
Claims46
A method of reducing IL-8, IL-6, IL-1β, and/or TNFα expression levels in a human subject in need thereof, comprising orally administering to the subject a Prevotella histicola strain comprising at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of the Prevotella Strain B 50329 (NRRL accession number B 50329).
A method of treating a viral infection in a subject comprising orally administering to the subject a Prevotella histicola strain comprising at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of the Prevotella Strain B 50329 (NRRL accession number B 50329).
A method of treating COVID-19 in a subject comprising orally administering to the subject a Prevotella histicola strain comprising at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of the Prevotella Strain B 50329 (NRRL accession number B 50329).
A method of identifying a subject as being at risk for increased severity of a disease or condition, the method comprising determining expression levels IL-8, IL-6, IL-1β, and/or TNFα in a sample from the subject, wherein elevated expression levels of IL-8, IL-6, IL-1β, and/or TNFα in the sample indicate that the subject is at of increased severity of the disease or condition.
Dependencies are inferred from the claim text.